Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$2.1M
6M shares
52-week range
$0.29 – $14.14
0% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
253.94%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $43.5K | $208.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | 0.0% | 0.0% | — | — | — | — | — | — |
| R&D | $3.0M | $1.6M | $1.5M | $1.8M | $2.0M | $4.7M | $9.5M | $9.8M |
| Operating income | $6.5M | $3.5M | −$3.1M | −$4.0M | −$4.4M | −$7.1M | −$14.5M | −$16.1M |
| EBITDA | −$6.6M | −$3.5M | −$3.1M | −$3.9M | −$4.4M | −$7.1M | −$21.9M | −$19.3M |
| Net income | −$6.7M | −$3.5M | −$2.7M | −$4.1M | −$4.4M | −$7.1M | −$22.6M | −$19.4M |
| Net margin | -15442.0% | -1690.4% | — | — | — | — | — | — |
| EPS (diluted) | 0.00 | -29.50 | -17.88 | -26.32 | -28.66 | -38.30 | 60.76 | -21.56 |
Annual figures · source: Financial Modeling Prep
GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.
www.glucotrack.comNo one on the platform currently holds GCTK.
No tracked institution reports a position in GCTK as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-06-16 | 1-for-60reverse |
| 2025-02-04 | 1-for-20reverse |
| 2024-05-20 | 1-for-5reverse |
No one on the platform has traded GCTK yet.
| $837 |
| — |
| HSCSHeartSciences Inc. | $2.75 | -6.46% | $6M | — |
| INMInMed Pharmaceuticals Inc. | $1.57 | +1.95% | $3M | — |
Source: Financial Modeling Prep · peers by sector/industry
$GCTK Diabetes affects roughly 1 in every 9 adults globally, including more than 38 million people in the United States alone, making it one of the most significant and widespread healthcare challenges of our time. Regardless of treatment strategy, medication, or insulin regimen, diabetes therapy often begins with one thing: understanding glucose levels. The information generated through glucose monitoring helps guide countless decisions made by people living with diabetes and healthcare providers every day. As a result, advances in how glucose is monitored measured have the potential to shape the broader standard of care. Meaningful advances begin with the people living everyday with diabetes and our desire to make their lives simpler and less burdensome. That core belief continues to guide our work every day.
View on StockTwits ↗$GCTK is this going to delist and go OTC? Can they even do another r/s?
View on StockTwits ↗$GCTK Behind every advancement in diabetes technology is a simple goal: helping people better manage their condition. People living with diabetes make decisions every day based on glucose information. We believe there remains an opportunity to expand how that information is collected and managed, thus simplifying the everyday management of diabetes. That belief is what moves us: By pursuing a new approach to glucose monitoring, we are working toward a future where innovation continues to push the boundaries of what is possible in diabetes care. Technology alone is not the goal. Creating new possibilities for people living with diabetes is.
View on StockTwits ↗$GCTK @Glucotrack_IR hearing rumors that the FDA denied your IDE.
View on StockTwits ↗$GCTK @Glucotrack_IR your shareholders would appreciate a status update on the IDE and any other information. Thankyou
View on StockTwits ↗$GCTK I have two AH buys in and slapped the ask. Not going thru??
View on StockTwits ↗$GCTK CBGM represents a new modality in glucose monitoring, and ongoing engagement with the FDA remains an important part of advancing the program. As previously communicated, we continue working toward regulatory alignment while progressing preparations for the planned clinical study and look forward to providing a further update on our progress in Q3. We want to keep shareholders informed as key development and regulatory milestones are reached, and we intend to continue sharing updates as progress is made.
View on StockTwits ↗$GCTK Hi there! One of the objectives of this account is to provide shareholders with direct updates regarding the company’s progress and key milestones. We look forward to continuing that communication as the CBGM program advances and additional developments become available.
View on StockTwits ↗$GCTK Thanks for the support. We view this account as a channel for sharing information and staying connected with our shareholder community. We intend to remain active here and will continue providing updates as they become available. We appreciate the engagement and look forward to keeping the conversation going as progress continues.
View on StockTwits ↗$GCTK We understand the interest in this topic and appreciate the question. As an official company account, we can only comment on information that has been publicly disclosed. Please know that we continue to actively work on our regulatory and compliance initiatives, as soon as there is information that can be publicly shared, we will communicate it. We remain committed to keeping shareholders informed of material developments as they become available.
View on StockTwits ↗@stockbot1234 $GCTK you left too early. Borrow rate is nuts.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.